
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Undisclosed
Recipient : Thor Medical
Deal Size : Undisclosed
Deal Type : Acquisition
Details : Through the acquisition, Nordic Nanovector gains access to highly promising new technology that enables the development and production of radionuclides for radioimmunoconjugate-based approaches to cancer treatment.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
June 06, 2023
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Undisclosed
Recipient : Thor Medical
Deal Size : Undisclosed
Deal Type : Acquisition

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Bupivacaine
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : APIM Therapeutics
Deal Size : Undisclosed
Deal Type : Merger
Nordic Nanovector and APIM Therapeutics Announce Merger Agreement
Details : ATX-101 is a first-in-class peptide targeting PCNA (Proliferating Cell Nuclear Antigen), a master regulator of cellular responses to stress and in tumour cell evasion from therapy. ATX-101 is currently being evaluated in platinum-sensitive ovarian cancer...
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
November 09, 2022
Lead Product(s) : Bupivacaine
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : APIM Therapeutics
Deal Size : Undisclosed
Deal Type : Merger

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : 177-Lu Lilotomab Satetraxetan
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Betalutin (177Lu lilotomab satetraxetan), is a next-generation single-dose CD37-directed radioimmunotherapy (RIT) for the treatment of Hodgkin B-cell lymphoma.
Product Name : Betalutin
Product Type : Miscellaneous
Upfront Cash : Inapplicable
July 05, 2022
Lead Product(s) : 177-Lu Lilotomab Satetraxetan
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : 177-Lu Lilotomab Satetraxetan,Lilotomab
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Betalutin® (177Lu Lilotomab Satetraxetan), showed signs of efficacy in this frail, elderly and difficult-to-treat patient population, the independent expert panel reported that the efficacy data are less promising than the data reported from the Phase 2...
Product Name : Betalutin
Product Type : Miscellaneous
Upfront Cash : Inapplicable
June 21, 2022
Lead Product(s) : 177-Lu Lilotomab Satetraxetan,Lilotomab
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Details : The primary objective of the PARADIGME trials is to determine the effectiveness of Betalutin (177Lu Lilotomab Satetraxetan), a novel single-dose radioimmunotherapy that targets CD37, an antigen found on the surface of tumour cells of Follicular Lymphoma.
Product Name : Betalutin
Product Type : Miscellaneous
Upfront Cash : Inapplicable
June 02, 2022

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : 177-Lu DOTA-NNV003,Olaparib
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : AstraZeneca
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Humalutin® (177Lu-DOTA-NNV003), acts by inducing potentially cytotoxic DNA breaks in the NHL cells, sensitising these cells to olaparib, which prevents repair of DNA breaks by blocking activity of DNA repair enzymes poly (ADP ribose) polymerase 1 and 2 ...
Product Name : Humalutin
Product Type : Radiolabeled Compound
Upfront Cash : Inapplicable
May 03, 2022
Lead Product(s) : 177-Lu DOTA-NNV003,Olaparib
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : AstraZeneca
Deal Size : Inapplicable
Deal Type : Inapplicable

Details : 106 patients has been enrolled for PARADIGME, ongoing pivotal Phase 2b trial of Betalutin (177Lu lilotomab satetraxetan) for the treatment of anti-CD20 refractory follicular lymphoma.PARADIGME data to be reported in second half of 2022.
Product Name : Betalutin
Product Type : Miscellaneous
Upfront Cash : Inapplicable
January 07, 2022

Nordic Nanovector to Present at 3rd Targeted Radiopharmaceutical Summit 2021
Details : Betalutin® (177Lu-lilotomab satetraxetan), an anti-CD37 beta-emitting radioimmuno conjugate has shown an encouraging efficacy and safety profile in 3rd line NHL patients who are refractory to anti-CD20-based treatments.
Product Name : Betalutin
Product Type : Miscellaneous
Upfront Cash : Inapplicable
December 07, 2021

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : 177-Lu Lilotomab Satetraxetan
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : ICON Clinical Research
Deal Size : Inapplicable
Deal Type : Inapplicable
Nordic Nanovector Sees Significant Improvement in Patient Recruitment Rate in PARADIGME
Details : Nordic Nanovector's lead clinical-stage candidate is Betalutin®, a novel CD37-targeting radioimmunotherapy designed to advance the treatment of non-Hodgkin's lymphoma (NHL).
Product Name : Betalutin
Product Type : Miscellaneous
Upfront Cash : Inapplicable
February 18, 2021
Lead Product(s) : 177-Lu Lilotomab Satetraxetan
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : ICON Clinical Research
Deal Size : Inapplicable
Deal Type : Inapplicable

Details : Nordic Nanovector has completed enrolment into the LYMRIT 37-05 Phase 1 clinical trial of Betalutin® (177Lu lilotomab satetraxetan) in patients with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) not eligible for autologous stem cell tran...
Product Name : Betalutin
Product Type : Miscellaneous
Upfront Cash : Inapplicable
December 01, 2020
